Pettee Krista M, Becker Kathryn N, Alberts Arthur S, Reinard Kevin A, Schroeder Jason L, Eisenmann Kathryn M
Department of Cancer Biology, University of Toledo Health Science Campus, Toledo, OH 43614, USA.
Laboratory of Cell Structure and Signal Integration, Van Andel Research Institute, Grand Rapids, MI 49503, USA.
Cancers (Basel). 2019 Mar 20;11(3):392. doi: 10.3390/cancers11030392.
High-grade glioma (HGG, WHO Grade III⁻IV) accounts for the majority of adult primary malignant brain tumors. Failure of current therapies to target invasive glioma cells partly explains the minimal survival advantages: invasive tumors lack easily-defined surgical margins, and are inherently more chemo- and radioresistant. Much work centers upon Rho GTPase-mediated glioma invasion, yet downstream Rho effector roles are poorly understood and represent potential therapeutic targets. The roles for the mammalian Diaphanous (mDia)-related formin family of Rho effectors have emerged in invasive/metastatic disease. mDias assemble linear F-actin to promote protrusive cytoskeletal structures underlying tumor cell invasion. Small molecule mDia intramimic (IMM) agonists induced mDia functional activities including F-actin polymerization. mDia agonism inhibited polarized migration in Glioblastoma (WHO Grade IV) cells in three-dimensional (3D) in vitro and rat brain slice models. Here, we evaluate whether clinically-relevant high-grade glioma patient-derived neuro-sphere invasion is sensitive to formin agonism. Surgical HGG samples were dissociated, briefly grown as monolayers, and spontaneously formed non-adherent neuro-spheres. IMM treatment dramatically inhibited HGG patient neuro-sphere invasion, both at neuro-sphere embedding and mid-invasion assay, inducing an amoeboid morphology in neuro-sphere edge cells, while inhibiting actin- and tubulin-enriched tumor microtube formation. Thus, mDia agonism effectively disrupts multiple aspects of patient-derived HGG neuro-sphere invasion.
高级别胶质瘤(HGG,世界卫生组织III-IV级)占成人原发性恶性脑肿瘤的大多数。目前的治疗方法无法靶向侵袭性胶质瘤细胞,这在一定程度上解释了生存优势为何极小:侵袭性肿瘤缺乏易于界定的手术切缘,并且本质上对化疗和放疗更具抗性。许多研究工作聚焦于Rho GTP酶介导的胶质瘤侵袭,但Rho下游效应子的作用却知之甚少,它们代表着潜在的治疗靶点。在侵袭性/转移性疾病中,Rho效应子的哺乳动物Diaphanous(mDia)相关formin家族的作用已逐渐显现。mDia组装线性F-肌动蛋白以促进肿瘤细胞侵袭所依赖的突出细胞骨架结构。小分子mDia内模拟物(IMM)激动剂可诱导mDia的功能活性,包括F-肌动蛋白聚合。在三维(3D)体外和大鼠脑片模型中,mDia激动作用抑制了胶质母细胞瘤(世界卫生组织IV级)细胞的极化迁移。在此,我们评估临床相关的高级别胶质瘤患者来源的神经球侵袭是否对formin激动作用敏感。将手术切除的HGG样本解离,短暂单层培养,然后自发形成非贴壁神经球。IMM处理在神经球包埋和侵袭中期试验中均显著抑制了HGG患者神经球的侵袭,在神经球边缘细胞中诱导出阿米巴样形态,同时抑制富含肌动蛋白和微管蛋白的肿瘤微管形成。因此,mDia激动作用有效地破坏了患者来源的HGG神经球侵袭的多个方面。